Estriol Dosage Adjustment for Cortical Gray Matter Atrophy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for relapsing-remitting multiple sclerosis, including estriol, often fail to effectively treat all patients and are associated with undesirable side effects, highlighting the need for alternative approaches to manage the disease, particularly in reducing cortical gray matter atrophy.
Innovation Solution
The method involves measuring serum estriol concentrations in patients and adjusting the estriol treatment regimen based on threshold values, with concurrent administration of glatiramer acetate, to optimize estriol levels within a therapeutic window, potentially incorporating progestogen for specific treatment periods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If estriol is administered to treat relapsing-remitting multiple sclerosis, then disease activity is reduced, but serum estriol levels may be insufficient to achieve optimal therapeutic effect
Solution Approach 1:
The patent implements a feedback mechanism by measuring serum estriol concentrations and using these measurements to guide treatment decisions. When levels are below the therapeutic threshold of 6 ng/mL, the dosage is increased; when levels are adequate, the original dosage is maintained. This closed-loop feedback system ensures reliable therapeutic effect by dynamically adjusting estriol quantity based on actual serum levels.
Solution Approach 2:
The patent changes the dosage parameter of estriol based on measured serum concentrations. The dosage is adjusted from the original amount to a higher amount when serum levels fall below 6 ng/mL, and maintained at the original amount when levels are sufficient. This parameter adjustment resolves the contradiction by optimizing the quantity of substance to achieve reliable therapeutic effect.
2Reliability
If estriol dosage is increased to achieve therapeutic levels, then gray matter atrophy is reduced, but treatment complexity increases
Solution Approach 1:
The treatment regimen uses feedback from serum estriol measurements to determine dosage adjustments. Rather than universally increasing dosage for all patients, the feedback mechanism identifies only those who need higher doses (those with levels below 6 ng/mL), keeping the treatment protocol simple for others. This resolves the contradiction by making complexity conditional rather than universal.
Solution Approach 2:
The patent applies partial action by increasing estriol dosage only for the subset of patients who demonstrate insufficient serum levels, rather than increasing dosage for all patients. This selective approach achieves the protective effect against gray matter atrophy where needed while avoiding unnecessary complexity for patients who are already receiving adequate therapy.
3Reliability
If serum estriol levels are monitored and adjusted, then therapeutic outcomes are improved, but measurement and treatment adjustment requirements increase
Solution Approach 1:
The patent establishes a feedback system where serum estriol measurements automatically inform treatment decisions. The clear threshold of 6 ng/mL provides an objective criterion that reduces the need for complex clinical judgment, thereby improving reliability while minimizing the extent of manual intervention required. The feedback loop is simple: measure, compare to threshold, and adjust accordingly.
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 2C
AI summary
Provided are methods for treating a neurodegenerative disease, such as multiple sclerosis, in a subject receiving a first estriol treatment regimen, comprising obtaining a measurement of the serum estriol concentration in the blood of the subject, and administering a second estriol treatment regimen to the subject if the serum estriol concentration is less than 6 ng/mL. The daily amount of estriol administered during the second estriol treatment regimen is preferably greater than the daily amount of estriol administered during the first estriol treatment regimen.